Search in:

Acta Cardiologica Volume 74, 2019 - Issue 1

Submit an article Journal homepage

151

Views

CrossRef citations to date

Altmetric

Viewpoint

NOACs only for those who cannot tolerate a VKA: where is the evidence?

Vinai C. BhagirathDepartment of Medicine, McMaster University, Hamilton, Canada; ;Population Health Research Institute, Hamilton, Canada; Correspondence[email protected]
View further author information

Bernard CosynsDepartment of Cardiology, Vrije Universiteit Brussel, Brussels, Belgium; ;Centrum voor Haart- en Vaatziekten, Brussels, BelgiumView further author information

John W. EikelboomDepartment of Medicine, McMaster University, Hamilton, Canada; ;Population Health Research Institute, Hamilton, Canada; View further author information

Pages 17-20 | Received 06 Feb 2018, Accepted 10 Feb 2018, Published online: 23 Feb 2018

Cite this article
https://doi.org/10.1080/00015385.2018.1442780
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Van Brabandt H, San Miguel L, Fairon N, et al. Anticoagulants in non-valvular atrial fibrillation. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2016. KCE Reports 279. D/2016/10.273/101.
Google Scholar
Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388:1161–1169.
Web of Science ®Google Scholar
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
PubMed Web of Science ®Google Scholar
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
PubMed Web of Science ®Google Scholar
Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147:590–592.
PubMed Web of Science ®Google Scholar
Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322:863–868.
PubMed Web of Science ®Google Scholar
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687–691.
PubMed Web of Science ®Google Scholar
Dolan G, Smith LA, Collins S, et al. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. Curr Med Res Opin. 2008;24:1459–1472.
PubMed Web of Science ®Google Scholar
Claes N, Van Laethem C, Goethals M, et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol. 2012;67:273–278.
PubMed Web of Science ®Google Scholar
Claes N, Buntinx F, Vijgen J, et al. Quality assessment of oral anticoagulation in Belgium, as practiced by a group of general practitioners. Acta Cardiol. 2005;60:247–252.
Web of Science ®Google Scholar
Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279:1273–1277.
PubMed Web of Science ®Google Scholar
Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912.
PubMed Web of Science ®Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
PubMed Web of Science ®Google Scholar
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
PubMed Web of Science ®Google Scholar
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
PubMed Web of Science ®Google Scholar
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
PubMed Web of Science ®Google Scholar
Miller CS, Dorreen A, Martel M, et al. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1674–1683.e3.
PubMed Web of Science ®Google Scholar
Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.
PubMed Web of Science ®Google Scholar
Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3:e000521.
PubMed Web of Science ®Google Scholar
Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–1872.
PubMed Web of Science ®Google Scholar
Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127:2166–2176.
PubMed Web of Science ®Google Scholar
Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209–218.
PubMed Web of Science ®Google Scholar
Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of Nonvitamin-K antagonist oral anticoagulants versus Vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48:2494–2503.
PubMed Web of Science ®Google Scholar
Buchheit J, Reddy P, Connors JM. Idarucizumab (Praxbind) formulary review. Crit Pathw Cardiol. 2016;15:77–81.
PubMedGoogle Scholar
Eikelboom JW, Quinlan DJ, Hirsh J, et al. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2:566–574.
PubMed Web of Science ®Google Scholar
Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41–46.
PubMed Web of Science ®Google Scholar
Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–140.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

NOACs only for those who cannot tolerate a VKA: where is the evidence?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

NOACs only for those who cannot tolerate a VKA: where is the evidence?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date